TR201903465T4 - Presbiyopi, hafif hiperopi ve düzensiz astigmatizmin tedavi edilmesine yönelik bileşimler ve yöntemler. - Google Patents

Presbiyopi, hafif hiperopi ve düzensiz astigmatizmin tedavi edilmesine yönelik bileşimler ve yöntemler. Download PDF

Info

Publication number
TR201903465T4
TR201903465T4 TR2019/03465T TR201903465T TR201903465T4 TR 201903465 T4 TR201903465 T4 TR 201903465T4 TR 2019/03465 T TR2019/03465 T TR 2019/03465T TR 201903465 T TR201903465 T TR 201903465T TR 201903465 T4 TR201903465 T4 TR 201903465T4
Authority
TR
Turkey
Prior art keywords
compositions
methods
irregular astigmatism
nsaid
cox
Prior art date
Application number
TR2019/03465T
Other languages
English (en)
Inventor
Carlos Abad Jaun
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47522725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201903465(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of TR201903465T4 publication Critical patent/TR201903465T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

Mevcut buluş, presbiyopi, hafif hiperopi, düzensiz astigmatizm, hiperopik akomodatif esotropi, ve glokom dâhil olmak üzere oküler bozuklukların tedavisine yönelik bileşimler ve yöntemler ile ilgilidir. Bileşimler ayrıca, kristalin lensin ve çevresindeki dokuların yaşlanma prosesini geciktiren, tersine çeviren veya değiştiren müdahalelerin dozunun artırılması veya desteklenmesi için kullanılabilmektedir. Bileşimler, bir muskarinik asetilkolin reseptör M3 agonist, ve bir imidazolin grubuna sahip bir alfa agonist veya COX-2 seçiciliğine sahip bir steroid olmayan anti inflamatuvar ajan (NSAID) gibi bir kolinerjik ajan içermektedir. Bir imidazolin grubuna sahip bir alfa agonistin veya pilokarpin gibi bir kolinerjik ajan ile birlikte COX-2 seçiciliğine sahip steroid olmayan anti inflamatuvar ajanın (NSAID), her bir bileşikten kaynaklanan yan etkileri en aza indirirken gözün akomodatif ve odaklama becerisini sinerjistik bir şekilde iyileştirme işlevi gördüğü bulunmuştur.
TR2019/03465T 2011-09-20 2012-09-19 Presbiyopi, hafif hiperopi ve düzensiz astigmatizmin tedavi edilmesine yönelik bileşimler ve yöntemler. TR201903465T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161536921P 2011-09-20 2011-09-20

Publications (1)

Publication Number Publication Date
TR201903465T4 true TR201903465T4 (tr) 2019-04-22

Family

ID=47522725

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03465T TR201903465T4 (tr) 2011-09-20 2012-09-19 Presbiyopi, hafif hiperopi ve düzensiz astigmatizmin tedavi edilmesine yönelik bileşimler ve yöntemler.

Country Status (23)

Country Link
US (6) US9579308B2 (tr)
EP (3) EP2758047B1 (tr)
JP (1) JP6141850B2 (tr)
KR (1) KR102017916B1 (tr)
CN (1) CN104093404B (tr)
AU (2) AU2012311239B2 (tr)
BR (1) BR112014006607A2 (tr)
CA (2) CA2849366C (tr)
CL (1) CL2014000689A1 (tr)
CO (1) CO7000769A2 (tr)
DK (1) DK2758047T3 (tr)
ES (1) ES2715296T3 (tr)
HK (1) HK1198426A1 (tr)
IL (1) IL231631B (tr)
IN (1) IN2014CN02961A (tr)
MX (1) MX357635B (tr)
MY (1) MY168643A (tr)
RU (1) RU2630968C2 (tr)
SG (1) SG11201400828RA (tr)
TR (1) TR201903465T4 (tr)
UA (1) UA113525C2 (tr)
WO (1) WO2013041967A2 (tr)
ZA (1) ZA201402049B (tr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA2849366C (en) 2011-09-20 2019-09-10 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
TWI588560B (zh) 2012-04-05 2017-06-21 布萊恩荷登視覺協會 用於屈光不正之鏡片、裝置、方法及系統
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US9201250B2 (en) 2012-10-17 2015-12-01 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
EP2908773B1 (en) 2012-10-17 2024-01-03 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
ES2538551B1 (es) * 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
CA2973471A1 (en) 2015-01-12 2016-07-21 Kedalion Therapeutics, Inc. Micro-droplet delivery device and methods
CN104622800A (zh) * 2015-02-03 2015-05-20 吉林修正药业新药开发有限公司 苄达赖氨酸滴眼液及制备方法
CA2981070A1 (en) 2015-04-10 2016-10-13 Kedalion Therapeutics, Inc. Piezoelectric dispenser with replaceable ampoule
KR20180014825A (ko) 2015-06-18 2018-02-09 프레스바이오피아 세라피스, 엘엘씨 눈의 굴절 이상 치료 및 원거리 시력 개선용 조성물 및 방법
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CH711969A2 (it) * 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
AU2017311636B2 (en) 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
WO2018136618A2 (en) 2017-01-20 2018-07-26 Kedalion Therapeutics, Inc. Piezoelectric fluid dispenser
JP7436363B2 (ja) 2017-12-08 2024-02-21 ノバルティス アーゲー 流体送達アライメントシステム
US20190314196A1 (en) * 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
PL3681500T3 (pl) 2018-04-24 2022-08-01 Allergan, Inc. Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
WO2020252061A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Carabachol-bromonidine formulation to enhance anti-presbyopia effects
US20220175734A1 (en) * 2019-06-10 2022-06-09 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
JP2023523394A (ja) 2020-04-17 2023-06-05 ケダリオン セラピューティックス，インコーポレイテッド 流体力学的に起動される防腐剤無添加分注システム
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
AU2021338618B2 (en) * 2020-09-11 2024-02-01 Intratus-Nevada, Inc. Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity
MX2020012116A (es) * 2020-11-12 2022-08-09 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia.
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
CN116350790A (zh) * 2021-12-28 2023-06-30 沈阳兴齐眼药股份有限公司 组合物及其在制备用于治疗老花眼的药物中的用途
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3670087A (en) 1970-10-16 1972-06-13 Miles Lab Method of lowering intraocular pressure
US5122522A (en) 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5055467A (en) 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5776916A (en) 1990-07-10 1998-07-07 Gramer; Eugen Medicament for reducing the intraocular pressure
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JPH07508751A (ja) 1992-07-02 1995-09-28 テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド 老視治療のための方法および生産品
SE512871C2 (sv) 1992-08-20 2000-05-29 Santen Oy Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
AU754064B2 (en) 1998-05-15 2002-11-07 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drops
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
AU7581000A (en) 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
US6730065B1 (en) 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
AU1548001A (en) 1999-11-24 2001-06-04 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US6515006B2 (en) 2000-11-08 2003-02-04 Hmt Pharma, Inc. Ophthalmic formulation which modulates dilation
US20040078009A1 (en) 2002-10-17 2004-04-22 Lin J. T. Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means
US20050205101A1 (en) 2002-10-17 2005-09-22 Lin J T Combined pharmocological and surgical method and system for the treatment of eye disorders
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
DE602006008643D1 (de) 2006-12-18 2009-10-01 Jorge Luis Benozzi Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
TNSN08110A1 (en) 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
KR101239168B1 (ko) * 2008-08-08 2013-03-05 가부시끼가이샤 도시바 나노카본 생성 장치
US20110262544A1 (en) * 2008-10-21 2011-10-27 Pharmalight Inc. Ophthalmic administration of a composition including brimonidine as a mist
US20110091459A1 (en) 2008-12-11 2011-04-21 Auspex Pharmaceuticals, Inc. Imidazole modulators of muscarinic acetylcholine receptor m3
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
JP2012015266A (ja) 2010-06-30 2012-01-19 Sony Corp 半導体光増幅器
AR081049A1 (es) 2010-08-17 2012-06-06 Gonzalez Santos Alejandro Raul Medicamento oftalmico para el tratamiento de la hipermetropia
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
WO2012112566A1 (en) 2011-02-15 2012-08-23 Allergan, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CA2849366C (en) 2011-09-20 2019-09-10 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
ES2538551B1 (es) 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia

Also Published As

Publication number Publication date
US20140200211A1 (en) 2014-07-17
KR102017916B1 (ko) 2019-09-03
US20140113946A1 (en) 2014-04-24
MX2014003421A (es) 2014-10-17
RU2014115439A (ru) 2015-10-27
IL231631A0 (en) 2014-05-28
UA113525C2 (xx) 2017-02-10
KR20140076587A (ko) 2014-06-20
WO2013041967A9 (en) 2013-06-13
CN104093404A (zh) 2014-10-08
US20220040152A1 (en) 2022-02-10
US20160310466A1 (en) 2016-10-27
US20180333392A1 (en) 2018-11-22
AU2017239563B2 (en) 2019-09-26
WO2013041967A2 (en) 2013-03-28
EP2758047A2 (en) 2014-07-30
CO7000769A2 (es) 2014-07-21
NZ623037A (en) 2016-07-29
US9301933B2 (en) 2016-04-05
JP2014533238A (ja) 2014-12-11
AU2012311239A1 (en) 2014-04-10
HK1198426A1 (en) 2015-04-24
IN2014CN02961A (tr) 2015-07-03
MY168643A (en) 2018-11-27
SG11201400828RA (en) 2014-07-30
RU2630968C2 (ru) 2017-09-15
CN104093404B (zh) 2016-12-07
CA2849366A1 (en) 2013-03-28
ZA201402049B (en) 2015-11-25
CL2014000689A1 (es) 2015-01-09
AU2012311239B2 (en) 2017-10-19
CA2849366C (en) 2019-09-10
DK2758047T3 (en) 2019-04-01
EP3517111A2 (en) 2019-07-31
EP3517111A3 (en) 2019-12-11
ES2715296T3 (es) 2019-06-03
IL231631B (en) 2019-07-31
JP6141850B2 (ja) 2017-06-07
MX357635B (es) 2018-07-17
CA3049795A1 (en) 2013-03-28
AU2017239563A1 (en) 2017-10-26
EP2758047B1 (en) 2018-12-19
US9579308B2 (en) 2017-02-28
US20200069651A1 (en) 2020-03-05
WO2013041967A3 (en) 2013-08-01
EP4272743A2 (en) 2023-11-08
BR112014006607A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
TR201903465T4 (tr) Presbiyopi, hafif hiperopi ve düzensiz astigmatizmin tedavi edilmesine yönelik bileşimler ve yöntemler.
CO2020006009A2 (es) Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201591405A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
BR112014030678A2 (pt) formas cristalinas de um modulador de receptor de androgênio
CO7250451A2 (es) Formulación oftálmica y método para mitigar la presbicia
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
MY183449A (en) Formulations of quinones for the treatment of ophthalmic diseases
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
WO2012009171A3 (en) Compositions and methods of treatment of corneal endothelium disorders
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
IL282624A (en) Methods and compositions for the treatment of sight beard, mydriasis and other disorders of the eyes
EA201490539A1 (ru) Соединения и композиции в качестве ингибиторов c-kit киназы
BR112014011341A2 (pt) composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona
WO2016085939A3 (en) Compounds and methods of treating ocular disorders
EP4324454A3 (en) Cross-linking agents and associated methods
WO2019067405A3 (en) FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN
MA35937B1 (fr) Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium
WO2013152193A3 (en) Methods of treating proliferative disorders with malate or derivatives thereof
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
MX2018008272A (es) Compuestos antagonizantes del receptor a3 de la adenosina, metodo para prepararlos y uso medico de los mismos.